Aldosterone is associated with left ventricular hypertrophy in hemodialysis patients

Stefano, Greicy Mara Mengue Feniman De; Zanati-Basan, Silméia Garcia; Stefano, Laercio Martins De; Silva, Viviana Rugolo Oliveira e; Xavier, Patrícia Santi; Barretti, Pasqual; Franco, Roberto Jorge da Silva; Júnior, João Garcia Caramori; Martin, Luís Cuadrado

doi:10.1177/1753944716644583

Cited by 6 publications

(4 citation statements)

References 35 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have demonstrated a close correlation between FGF23 and the renin-angiotensin-aldosterone system (RAAS) [ 9 ]. The RAAS is an important system for controlling blood pressure (BP) and causes LVH [ 10 ]. Therefore, we focused on the RAAS as the common factor influencing the increase in FGF23 levels and the exacerbation of LVH.…”

mentioning

confidence: 99%

Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy

Okamoto

Fujii

Watanabe

et al. 2021

Journal of the Endocrine Society

View full text Add to dashboard Cite

Serum fibroblast growth factor 23 (FGF23) levels and the renin-angiotensin-aldosterone system (RAAS) are elevated in chronic kidney disease (CKD) patients, and their association with left ventricular hypertrophy (LVH) has been reported. However, whether the FGF23 elevation is the cause or result of LVH remains unclear. At 10 weeks, male C57BL/6J mice were divided into four groups: Sham, CKD (5/6 nephrectomy), LVH (transaortic constriction), and CKD/LVH group. At 16 weeks, the mice were sacrificed, and blood and urine, cardiac expressions of FGF23 and RAAS-related factors, and cardiac histological analyses were performed. Heart weight, serum FGF23 levels, and cardiac expression of FGF23 and RAAS-related factors, except for angiotensin-converting enzyme 2, more increased in the CKD/LVH group compared to the other groups. A significant correlation between LVH and cardiac expressions of FGF23 and RAAS-related factors was observed. Furthermore, there was a significantly close correlation of the cardiac expression of FGF23 with LVH and RAAS-related factors. The coexisting CKD and LVH increased serum and cardiac FGF23 and RAAS-related factors, and there was a significant correlation between them. A close correlation of cardiac, but not serum FGF23, with LVH and RAAS suggested that local FGF23 levels may be associated with LVH and RAAS activation.

show abstract

mentioning

confidence: 99%

Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy

Okamoto

Fujii

Watanabe

et al. 2021

Journal of the Endocrine Society

View full text Add to dashboard Cite

show abstract

“…Moreover, excess aldosterone affects LVH in patients with hypertension and CKD both on conservative and renal replacement therapy treatment (RRT) [12]. It also contributes to the aggravation of endothelial damage, inhibition of nitric oxide synthase (iNOS) activity, and impairment of endothelium-dependent vasodilation [13].…”

Section: Aldosterone and Cardiovascular Damage In Patients With Ckdmentioning

confidence: 99%

The role of aldosterone in kidney diseases and hypertension. Is it worth using mineralocorticoid receptor antagonists in clinical practice?

Donderski

Manitius

2019

Arterial Hypertension

View full text Add to dashboard Cite

Aldosterone is a mineralocorticoid hormone which plays a pivotal role in water and electrolytes balance. Moreover, aldosterone exerts a deleterious influence on the cardiovascular system and kidneys. In this review, we wanted to show mechanisms of aldosterone related organ damage, the role of aldosterone in kidney diseases, hypertension and therapeutic benefits related with aldosterone receptors blockade.

show abstract

“…In cardiac function, COX-2 inhibitors reduce myocardial damage and inflammation after cardiac allograft transplantation ( Ma et al., 2002 ). Intriguingly, COX-2 inhibitors or knockout mice improve cardiac hypertrophy and dysfunction after injury or stimulation in different adult models, such as MI, ischemia with reperfusion, abdominal aortic constrictions, and Ang II- and aldosterone-induced cardiac hypertrophy ( Camitta et al., 2001 ; Chi et al., 2017 ; Feniman De Stefano et al., 2016 ; Wu et al., 2005 ; Zhang et al., 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Celecoxib alleviates pathological cardiac hypertrophy and fibrosis via M1-like macrophage infiltration in neonatal mice

et al. 2021

View full text Add to dashboard Cite

show abstract

Aldosterone is associated with left ventricular hypertrophy in hemodialysis patients

Abstract: ClinicalTrials.gov identifier: NCT01128101.

Cited by 6 publications

References 35 publications

Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy

Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy

The role of aldosterone in kidney diseases and hypertension. Is it worth using mineralocorticoid receptor antagonists in clinical practice?

Celecoxib alleviates pathological cardiac hypertrophy and fibrosis via M1-like macrophage infiltration in neonatal mice

Contact Info

Product

Resources

About